BOEHRINGER INGELHEIM
About
Support the early Oncology clinical drug research and development process by providing strategic planning and execution, including clinical trial design and all aspects of descriptive, diagnostic, predictive and prescriptive analytics of data related to clinical projects like actual trial data, registries and real-world data bases. Represent biostatistics and coordinate the inputs from programing and data management at a substance/asset level regarding data science related aspects. Collaborat...
Updates & Highlights
Boehringer Ingelheim Expands NIPER Partnerships
Boehringer Ingelheim Expands NIPER Partnerships
Machine Maker · about 7 hours ago
Boehringer Ingelheim Says JASCAYD Approved In Japan, Advancing Global Access To New IPF & PPF Treatment
Boehringer Ingelheim Says JASCAYD Approved In Japan, Advancing Global Access To New IPF & PPF Treatment
TradingView · 4 days ago
Boehringer Ingelheim India, NIPER Collab to Expand Research Across Pharma Hubs
Boehringer Ingelheim India, NIPER Collab to Expand Research Across Pharma Hubs
Deccan Chronicle · 5 days ago
Recent Openings
View all 7 jobsSenior Data Scientist
Biberach an der Riß, BW, DE
(Senior) Data Scientist
Biberach an der Riß, BW, DE
Quality Medicine Data Scientist (m/f/d)
Wien, W, AT
(Senior) Principal Clinical Data Scientist
Biberach an der Riß, BW, DE
All Jobs
Senior Data Scientist
Biberach an der Riß, BW, DE
(Senior) Data Scientist
Biberach an der Riß, BW, DE
Quality Medicine Data Scientist (m/f/d)
Wien, W, AT
(Senior) Principal Clinical Data Scientist
Biberach an der Riß, BW, DE
Senior/Principal Clinical Data Scientist HTA
Biberach an der Riß, BW, DE
SR AD/ AD, Principal Clinical Data Scientist -Early Oncology Drug Development (Remote)
Ridgefield, CT, US
SR AD/ AD, Principal Clinical Data Scientist -Early Oncology Drug Development
Ridgefield, CT, US
Culture & Mission
Benefits & Perks
Competitive Salary
Market-rate compensation
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Equity/Stock Options
Ownership in the company
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Boehringer Ingelheim?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentBoehringer Ingelheim Expands NIPER Partnerships
Boehringer Ingelheim Expands NIPER Partnerships
Machine Maker · about 7 hours ago
Boehringer Ingelheim Says JASCAYD Approved In Japan, Advancing Global Access To New IPF & PPF Treatment
Boehringer Ingelheim Says JASCAYD Approved In Japan, Advancing Global Access To New IPF & PPF Treatment
TradingView · 4 days ago
Boehringer Ingelheim India, NIPER Collab to Expand Research Across Pharma Hubs
Boehringer Ingelheim India, NIPER Collab to Expand Research Across Pharma Hubs
Deccan Chronicle · 5 days ago
Boehringer Ingelheim Secures Next-Generation Autoimmune Therapy Candidate
Boehringer Ingelheim Secures Next-Generation Autoimmune Therapy Candidate
thelec.net · 8 days ago
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
Manufacturing Chemist · 8 days ago
Boehringer Ingelheim licenses Immunitas antibody program
Boehringer Ingelheim licenses Immunitas antibody program
BioWorld News · 8 days ago
Boehringer Ingelheim deepens AI imaging pact with Brainomix in new fibrosis study
Boehringer Ingelheim deepens AI imaging pact with Brainomix in new fibrosis study
FirstWord Pharma · 9 days ago
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
Pharmaceutical Executive · 9 days ago
Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care
Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care
Contract Pharma · 9 days ago
Brainomix, Boehringer Ingelheim Advance Partnership in Pulmonary Fibrosis
Brainomix, Boehringer Ingelheim Advance Partnership in Pulmonary Fibrosis
Medical Product Outsourcing · 9 days ago
Brainomix and Boehringer Ingelheim advance strategic partnership in pulmonary fibrosis
Brainomix and Boehringer Ingelheim advance strategic partnership in pulmonary fibrosis
PharmaLive · 9 days ago
Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
PR Newswire · 9 days ago
The Escalator: Johnson & Johnson, Fingerpaint Group, Boehringer Ingelheim and more
The Escalator: Johnson & Johnson, Fingerpaint Group, Boehringer Ingelheim and more
Medical Marketing and Media · 14 days ago
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
PR Newswire · 15 days ago
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
PR Newswire · 15 days ago
Boehringer Ingelheim’s Obesity Drug Helps Lose Fat Rather Than Muscle, Late-Stage Trial Shows
Boehringer Ingelheim’s Obesity Drug Helps Lose Fat Rather Than Muscle, Late-Stage Trial Shows
WSJ · 24 days ago
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Boehringer Ingelheim · 24 days ago
The Atlanta Braves and Boehringer Ingelheim unveil 2026 “Dogout” to honor veterinarians
The Atlanta Braves and Boehringer Ingelheim unveil 2026 “Dogout” to honor veterinarians
Boehringer Ingelheim · 29 days ago
Boehringer Ingelheim launches AI centre for pharma research in London
Boehringer Ingelheim launches AI centre for pharma research in London
Reuters · about 1 month ago
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Boehringer Ingelheim · about 1 month ago